Syndros is an cannabinoid drug owned by Benuvia. The active ingredient in Syndros is dronabinol. This drug was first authorized for market use on March 23, 2017, and it's available in solution; oral dosage forms. Syndros holds a total of 4 drug patents.
The generic versions of Syndros are expected to become available after August 06, 2028, when the last drug patent expires. This is the anticipated release date of the Syndros generic.
Syndros holds a total of 4 drug patents, none of which have expired. The last patent is expected to expire on August 6, 2028, after which the Syndros generic could potentially be released. Below are the details of the patent: